| Iupac name | 2-Methyl-4-[4-nitro-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazinan-3-one |
|---|---|
| Width | 225px |
| Class | Nonsteroidal antiandrogen |
| Cas number | 63094-42-8 |
| Unii | 99QTV3S3MG |
| Pubchem | 9948430 |
| Chemspiderid | 8124041 |
| Synonyms | 5,6-Dihydro-2-methyl-4-[4-nitro-3-(trifluoromethyl)phenyl]-2H-1,2,4-oxadiazin-3-(4H)-one[1] |
| C | 11 |
| H | 10 |
| F | 3 |
| N | 3 |
| O | 4 |
| Smiles | CN1OCCN(C1=O)C1=CC=C(C(=C1)C(F)(F)F)N(=O)=O |
| Stdinchi | 1S/C11H10F3N3O4/c1-15-10(18)16(4-5-21-15)7-2-3-9(17(19)20)8(6-7)11(12,13)14/h2-3,6H,4-5H2,1H3 |
| Stdinchikey | SQAORNVRAYTOMS-UHFFFAOYSA-N |
RU-22930 is a nonsteroidal antiandrogen (NSAA) related to the NSAAs flutamide and nilutamide (RU-23908) and was developed by Roussel Uclaf but was never marketed.[2][3] It is a selective antagonist of the androgen receptor and consequently has progonadotropic effects by increasing gonadotropin and testosterone levels via disinhibition of the hypothalamic-pituitary-gonadal axis.[2] Unlike flutamide and nilutamide, the drug is said to be short-acting and inactive by injection, but it has been found to be active topically in animals, and hence could be useful for the treatment of androgen-dependent skin conditions.[2][4]
See also
References
- ^ "Compositions and methods for inhibiting the action of androgens"
- ^ Tindall DJ, Chang CH, Lobl TJ, Cunningham GR (1984). "Androgen antagonists in androgen target tissues". Pharmacol. Ther.. 24 (3): 367–400. doi:10.1016/0163-7258(84)90010-x. PMID 6205409
- ^ Singh SM, Gauthier S, Labrie F (2000). "Androgen receptor antagonists (antiandrogens): structure-activity relationships". Curr. Med. Chem.. 7 (2): 211–47. doi:10.2174/0929867003375371. PMID 10637363
- ^ Thomson, D. S. (1989). "Pharmacology of Anti-androgens in the Skin". Pharmacology of the Skin II. Vol. 87 / 2. Handbook of Experimental Pharmacology. pp. 483–493. doi:10.1007/978-3-642-74054-1_36. ISBN 978-3-642-74056-5. ISSN 0171-2004